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Emphysema is a very com­
mon cause of morbidity and 
mortality in South Africa 
(SA). Smoking remains the 
most common risk factor for 
the development of emphysema, but long­
term biomass fuel exposure, tuberculosis and 
HIV co­infection contribute to the disease 
burden in southern Africa.[1] However, 
therapeutic options for severe emphysema 
are currently limited.
In the subgroup of patients with pre­
dominantly upper­lobe emphysema and 
low exercise capacity, surgical lung volume 
reduction improves functional status, but 
not without a significant risk of mortality 
and morbidity as well as high financial 
costs.[2] Endoscopic lung volume reduction 
(ELVR), which is increasingly being used 
internationally, aims to reduce the risks 
and costs of surgery, while obtaining the 
same functional advantages. It refers to the 
placement of a device (e.g. a valve or coil) 
through a bronchoscope into a bronchus 
with the aim of decreasing the volume 
of the lung segments distal to the device, 
thereby improving pulmonary mechanics 
and compliance.[3] The work of breathing is 
reduced, resulting in significant improvements 
in symptoms, particularly breathlessness.
There is a growing body of evidence that 
certain well­defined subgroups of patients 
with advanced emphysema benefit from 
ELVR, with the caveat that a systematic 
approach is followed and selection criteria 
are met. Recently, endobronchial coils, in 
addition to endobronchial valves, have 
become available in SA for ELVR; however, 
the cost of both remains high, emphasising 
the need for careful patient identification 
and selection to best identify those who are 
most likely to benefit from these procedures.
Modalities and devices 
available in SA
Unidirectional endobronchial and 
intrabronchial valves
Unidirectional valves induce either lobar 
or segmental lung collapse by preventing 
the entrance of air during inspiration, while 
allowing exhalation of air and secretions. 
There are currently two such devices 
commercially available in SA: Zephyr endo­
bronchial valves (Pulmonx Inc.) (Fig. 1) 
and IBV intrabronchial valves (Olympus 
Respiratory America) (Fig. 2). Both devices 
are self­expanding and delivered using a 
catheter introduced through the working 
channel of a flexible bronchoscope.[3]
These devices have been shown to be 
less effective when emphysema is found 
uniformly throughout the lungs (i.e. homo­
geneous emphysema). The distri bution of 
emphysema is assessed on high­resolution 
computed tomography (HRCT) scanning 
of the chest, either by visual inspection of 
the parenchyma or by using specifically 
designed automated quantification soft­
ware.[3] Additionally, valves fail to induce 
collapse when the affected portion of the 
lung has collateral ventilation. This is a 
normal physiological phenomenon in 
many individuals, but significant interlobar 
collateral ventilation subverts the deflating 
effect of endobronchial blocking devices. 
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Fig. 1. An endobronchial (Zephyr) valve.
Fig. 2. An intrabronchial (IBV) valve.
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Prior to placement of a valve, both hom­
ogeneous emphysema and collateral venti­
lation therefore need to be excluded. The 
evidence for this requirement is derived 
from numerous studies in which the 
minimal clinically important differences 
were significantly more likely to be observed 
in patients with advanced heterogeneous 
emphysema and no collateral ventilation. 
Moreover, unilateral (as opposed to bilateral 
ELVR) valve placement was found to have 
better outcomes.[4­7]
The recently completed STELVIO trial 
provided the strongest evidence for use 
of valves in patients without collateral 
ventilation.[8] Dutch investigators random­
ised 68 patients with severe emphysema on 
HRCT with visual estimation of complete 
or near­complete fissures to endobronchial 
Zephyr valve treatment (n=34) or standard 
medical care (n=34). The primary outcome 
measures were change in spirometric 
measures and the 6­minute walking distance 
(6MWD) at 6  months. Clinical relevance 
was assessed relative to minimal clinically 
important differences. At 6 months, the 
minimal clinically important differences 
were attained in all parameters in the treated 
group compared with controls (p<0.001 for 
all endpoints).
The most common reported adverse 
events experienced with endobronchial 
valve placement have been pneumothoraces 
(5 ­ 10%), mild haemoptysis (2 ­ 6%) 
and exacerbations of underlying chronic 
obstructive pulmonary disease (COPD) (8 ­ 
40%).[4­7]
Coils
Coils (RePneu; BTG Inc.) (Fig. 3) are nitinol 
devices designed to be deployed into a 
straight airway, and thereafter to resume 
their preformed shape. This conformational 
shape change after deployment results in 
parenchymal retraction with volume loss, 
while maintaining airway patency.[9] The 
device is currently available in three lengths 
to accommodate different­sized airways. 
The coils are implanted via a flexible 
bronchoscope under general anaesthesia 
or conscious sedation and fluoroscopic 
guidance using a proprietary delivery system. 
In theory, coils not only cause lung volume 
reduction but additionally re­tension the 
remaining airway network and mechanically 
increase elastic recoil. This re­tensioning 
of the lung tethers open the small airways, 
thus preventing their collapse on expiration, 
known to be the pathogenetic mechanism of 
emphysema.
Current evidence suggests that candi­
dates with both heterogeneous and homo­
geneous emphysema can experience 
clinically signi ficant benefit from ELVR 
using coils. This benefit is obtained 
regardless of the presence of collateral 
ventilation or complete lobar collapse post 
procedure, but requires that least >25% of 
the total lung paren chyma is unaffected 
by radiological emphysema prior to 
insertion.[10,11] Approxi mately 75 ­ 80% of 
patients will experience minimal clinically 
important differences in lung function and 
quality of life, while mild haemoptysis of 
<5 mL (50 ­ 75%), exacerbations of COPD 
(5 ­ 12%), mild chest discomfort (15 ­ 50%) 
and infrequent pneumothoraces (3%) are 
the described adverse events.[10,11] A recent 
report on the 3­year follow up data on 
38 patients who underwent ELVR using 
coils suggested that the coil treatment 
was safe; no late pneumothoraces, coil 
migrations or unexpected adverse events 
occurred.[12] Although clinical benefit grad­
ually declined over time, at 3 years post 
treatment approximately 50% of the patients 
maintained improvement in 6MWD and 
dyspnoea and quality of life scores.
Other devices
Synthetic polymeric foam (Aeris Thera­
peutics Biological) has been used to obtain 
atelectasis. This technology is currently not 
available in SA. A recent study on synthetic 
polymeric foam, which was terminated 
prematurely, raised some safety concerns.[13]
The future of endoscopic 
lung volume reduction 
in SA
Current evidence suggests that not all 
classes and phenotypes of emphysema will 
benefit from ELVR, and that individual 
techniques offer benefit to different 
subgroups of patients.[5,9,10] Only a few 
centres in SA currently have the capacity 
to evaluate prospective candidates properly 
and potentially offer ELVR to appropriate 
cases. The high cost of these interventions 
makes careful patient selection imperative to 
prevent wasteful treatment of patients who 
are unlikely to gain clinical benefit.
The initial screening for suitable candidates 
should be performed at subspecialist (pul­
monologist) level, and on patients with 
stable disease and no recent exacerbations. 
Routine special investigations should include 
HRCT (to estimate heterogeneity, integrity 
of fissures and degree of tissue destruction, 
and evaluate for possible underlying lung 
cancer), full pulmonary function testing, 
arterial blood gas measurement and echo­
cardiography (to exclude pulmonary 
hypertension).[10] The general indications 
and contraindications for valves and coils 
are summarised in Table 1. ELVR should not 
be offered to active smokers, patients with 
pulmonary hypertension, unstable cardiac 
pathology, active respiratory infections or 
very poor exercise tolerance, patients without 
clear evidence of hyperinflation, or patients 
who use antiplatelet or anticoagulant therapy 
that cannot be stopped for 7 days prior to the 
procedure.[10,11,14]
Appropriate or borderline candidates 
(Table 1) should be referred to a centre with 
the capacity to evaluate, treat and follow 
up these patients, and manage compli­
cations and undertake removal of devices 
if required.
Conclusions and 
recommendations
There is currently no head­to­head evidence 
comparing the various techniques and 
devices, and no official guideline from any 
of the major thoracic societies is currently 
available. The Assembly on Interventional 
Pulmonology of the South African Thoracic 
Society has extensively reviewed all relevant 
publications, and consulted international 
experts on the use of ELVR in SA in the 
form of recommendations based not only 
on published evidence, international expert 
opinion and local expertise, but also on 
local commercial access to devices.[14] It 
is also recommended that all endoscopic 
lung volume reduction procedures should 
be performed in the context of a local and/
or international registry. The Assembly 
on Interventional Pulmonology of the SA 
Thoracic Society is willing to assist potential 
centres wishing to establish an ELVR service 
in terms of training and accreditation.
In summary, appropriate candidates 
with marked hyperinflation and relatively 
preserved lung parenchyma are more likely 
to benefit from ELVR with bilateral coils, 
irrespective of the collateral ventilation and 
heterogeneity of the disease. In contrast, 
patients with heterogeneous disease and 
no collateral ventilation are more likely to 
benefit from unilateral ELVR with valves 
aiming to achieve complete lobar collapse. Fig. 3. An endobronchial (RePneu) coil.
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A well­structured evidence­based approach 
to ELVR, including initial screening and 
subsequent referral to a specialised centre, 
is important to avoid inappropriate use of 
devices, which may be both wasteful and 
harmful.
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Table 1. General indications and contraindications for endobronchial lung volume reduction 
with endobronchial and intrabronchial valves and coils in patients with stable emphysema
Indications
40 ­ 75 years
Heterogeneous emphysema and no collateral ventilation*
Dyspnoea despite maximal medical therapy and pulmonary rehabilitation
FEV1 15 ­ 45%
Hyperinflation with TLC >100% and RV >150 ­ 175%
PaCO2 <6.7 kPa (50 mmHg)
PaO2 >6 kPa (45 mmHg) while breathing ambient air
6MWD ≥140 m (post rehabilitation)
Contraindications
Homogeneous emphysema*
Collateral ventilation/non­intact fissures*
>75% parenchymal destruction on HRCT†
Current smoking (last 6 months)
DLCO <20% (relative contraindication)
Giant bullae (>1/3 of hemithorax)
Alpha­1­antitrypsin deficiency
Previous thoracotomy, pleurodesis or chest wall deformity
Excessive sputum
Severe pulmonary hypertension (>50 mmHg)
Active infection
Unstable cardiac conditions
Significant pleural or interstitial changes on HRCT
Any type of antiplatelet or anticoagulant therapy that cannot be stopped for 7 days prior to procedure
FEV1 = forced expiratory volume in 1 second; TLC = total lung capacity; RV = residual volume; PaCO2 = partial pressure of carbon 
dioxide; PaO2 = partial pressure of carbon dioxide; 6MWD = 6­minute walking distance; DLCO = carbon monoxide diffusing capacity.
*Specific for endobronchial and intrabronchial valves.
†Specific for endobronchial coils.
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